Cargando…
IL-6R/STAT3/miR-204 feedback loop contributes to cisplatin resistance of epithelial ovarian cancer cells
Enhanced chemoresistance is, among other factors, believed to be responsible for treatment failure and tumor relapse in patients with epithelial ovarian cancer (EOC). Here, we exposed EOC cells to interleukin-6 (IL-6) to activate oncogenic STAT3, which directly repressed miR-204 via a conserved STAT...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5503602/ https://www.ncbi.nlm.nih.gov/pubmed/28388577 http://dx.doi.org/10.18632/oncotarget.16610 |
_version_ | 1783249133822279680 |
---|---|
author | Zhu, Xiaolan Shen, Huiling Yin, Xinming Long, Lulu Chen, Xiaofang Feng, Fan Liu, Yueqin Zhao, Peiqing Xu, Yue Li, Mei Xu, Wenlin Li, Yuefeng |
author_facet | Zhu, Xiaolan Shen, Huiling Yin, Xinming Long, Lulu Chen, Xiaofang Feng, Fan Liu, Yueqin Zhao, Peiqing Xu, Yue Li, Mei Xu, Wenlin Li, Yuefeng |
author_sort | Zhu, Xiaolan |
collection | PubMed |
description | Enhanced chemoresistance is, among other factors, believed to be responsible for treatment failure and tumor relapse in patients with epithelial ovarian cancer (EOC). Here, we exposed EOC cells to interleukin-6 (IL-6) to activate oncogenic STAT3, which directly repressed miR-204 via a conserved STAT3-binding site near the TRPM3 promoter region upstream of miR-204. Repression of miR-204 was required for IL-6-induced cisplatin (cDDP) resistance. Furthermore, we identified the IL-6 receptor (IL-6R), which mediates IL-6-dependent STAT3 activation, as a direct miR-204 target. Importantly, the resulting IL-6R/STAT3/miR-204 feedback loop was identified in patients with EOC, and its activity correlated with chemosensitivity. Moreover, exogenous miR-204 blocked this circuit and enhanced cDDP sensitivity both in vitro and in vivo by inactivating IL-6R/STAT3 signaling and subsequently decreasing the expression of anti-apoptotic proteins. Our findings illustrate the function of this feedback loop in cDDP-based therapy and may offer a broadly useful approach to improve EOC therapy. |
format | Online Article Text |
id | pubmed-5503602 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-55036022017-07-11 IL-6R/STAT3/miR-204 feedback loop contributes to cisplatin resistance of epithelial ovarian cancer cells Zhu, Xiaolan Shen, Huiling Yin, Xinming Long, Lulu Chen, Xiaofang Feng, Fan Liu, Yueqin Zhao, Peiqing Xu, Yue Li, Mei Xu, Wenlin Li, Yuefeng Oncotarget Research Paper Enhanced chemoresistance is, among other factors, believed to be responsible for treatment failure and tumor relapse in patients with epithelial ovarian cancer (EOC). Here, we exposed EOC cells to interleukin-6 (IL-6) to activate oncogenic STAT3, which directly repressed miR-204 via a conserved STAT3-binding site near the TRPM3 promoter region upstream of miR-204. Repression of miR-204 was required for IL-6-induced cisplatin (cDDP) resistance. Furthermore, we identified the IL-6 receptor (IL-6R), which mediates IL-6-dependent STAT3 activation, as a direct miR-204 target. Importantly, the resulting IL-6R/STAT3/miR-204 feedback loop was identified in patients with EOC, and its activity correlated with chemosensitivity. Moreover, exogenous miR-204 blocked this circuit and enhanced cDDP sensitivity both in vitro and in vivo by inactivating IL-6R/STAT3 signaling and subsequently decreasing the expression of anti-apoptotic proteins. Our findings illustrate the function of this feedback loop in cDDP-based therapy and may offer a broadly useful approach to improve EOC therapy. Impact Journals LLC 2017-03-27 /pmc/articles/PMC5503602/ /pubmed/28388577 http://dx.doi.org/10.18632/oncotarget.16610 Text en Copyright: © 2017 Zhu et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Research Paper Zhu, Xiaolan Shen, Huiling Yin, Xinming Long, Lulu Chen, Xiaofang Feng, Fan Liu, Yueqin Zhao, Peiqing Xu, Yue Li, Mei Xu, Wenlin Li, Yuefeng IL-6R/STAT3/miR-204 feedback loop contributes to cisplatin resistance of epithelial ovarian cancer cells |
title | IL-6R/STAT3/miR-204 feedback loop contributes to cisplatin resistance of epithelial ovarian cancer cells |
title_full | IL-6R/STAT3/miR-204 feedback loop contributes to cisplatin resistance of epithelial ovarian cancer cells |
title_fullStr | IL-6R/STAT3/miR-204 feedback loop contributes to cisplatin resistance of epithelial ovarian cancer cells |
title_full_unstemmed | IL-6R/STAT3/miR-204 feedback loop contributes to cisplatin resistance of epithelial ovarian cancer cells |
title_short | IL-6R/STAT3/miR-204 feedback loop contributes to cisplatin resistance of epithelial ovarian cancer cells |
title_sort | il-6r/stat3/mir-204 feedback loop contributes to cisplatin resistance of epithelial ovarian cancer cells |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5503602/ https://www.ncbi.nlm.nih.gov/pubmed/28388577 http://dx.doi.org/10.18632/oncotarget.16610 |
work_keys_str_mv | AT zhuxiaolan il6rstat3mir204feedbackloopcontributestocisplatinresistanceofepithelialovariancancercells AT shenhuiling il6rstat3mir204feedbackloopcontributestocisplatinresistanceofepithelialovariancancercells AT yinxinming il6rstat3mir204feedbackloopcontributestocisplatinresistanceofepithelialovariancancercells AT longlulu il6rstat3mir204feedbackloopcontributestocisplatinresistanceofepithelialovariancancercells AT chenxiaofang il6rstat3mir204feedbackloopcontributestocisplatinresistanceofepithelialovariancancercells AT fengfan il6rstat3mir204feedbackloopcontributestocisplatinresistanceofepithelialovariancancercells AT liuyueqin il6rstat3mir204feedbackloopcontributestocisplatinresistanceofepithelialovariancancercells AT zhaopeiqing il6rstat3mir204feedbackloopcontributestocisplatinresistanceofepithelialovariancancercells AT xuyue il6rstat3mir204feedbackloopcontributestocisplatinresistanceofepithelialovariancancercells AT limei il6rstat3mir204feedbackloopcontributestocisplatinresistanceofepithelialovariancancercells AT xuwenlin il6rstat3mir204feedbackloopcontributestocisplatinresistanceofepithelialovariancancercells AT liyuefeng il6rstat3mir204feedbackloopcontributestocisplatinresistanceofepithelialovariancancercells |